---
id: 214
title: Osteomyelitis
category: clinical_syndromes
subcategory: bone_joint
tags: [osteomyelitis, bone-infection, MRSA, diabetic-foot, vertebral-osteomyelitis, bone-biopsy]
difficulty: high
---

## Question

How is osteomyelitis managed? Use **"Bone Biopsy for Micro → Pathogen-Directed IV Antibiotics × 6 Weeks, Surgery if Dead Bone/Abscess"** framework.

## Answer

### **Classification:**

**By Mechanism:**
- **Hematogenous** (25%): Bacteremia → bone
- **Contiguous focus** (50%): Direct spread from adjacent infection (diabetic foot, pressure ulcer, post-surgical)
- **Vascular insufficiency** (25%): Diabetic foot, peripheral arterial disease

**By Duration:**
- **Acute:** <2 weeks
- **Subacute:** 2 weeks to 3 months
- **Chronic:** >3 months (dead bone = sequestrum)

### **Microbiology:**

**Hematogenous:**
- ***Staphylococcus aureus*** (60-80%, most common)
- **Streptococci** (10-20%)
- **Gram-negatives** (*E. coli*, *Pseudomonas* in IVDU)
- ***Salmonella*** (sickle cell disease)

**Contiguous/Diabetic Foot:**
- **Polymicrobial** (50%)
- ***S. aureus*** (MSSA/MRSA)
- **Streptococci**
- **Gram-negatives** (*Proteus*, *E. coli*, *Pseudomonas*)
- **Anaerobes** (*Bacteroides*, *Peptostreptococcus*)

**Vertebral:**
- ***S. aureus*** (40-60%)
- **Coagulase-negative staphylococci** (especially post-surgical)
- **Gram-negatives** (*E. coli* - GU source)
- ***Mycobacterium tuberculosis*** (Pott disease)
- ***Brucella*** (endemic areas)

**Prosthetic Joint:**
- **See separate card**

### **Diagnosis:**

**Clinical:**
- **Bone pain, local tenderness** (may be subtle in chronic)
- **Fever** (acute, 50-60%)
- **Overlying cellulitis, sinus tract** (chronic)

**Labs:**
- **↑ESR, CRP** (sensitive, non-specific)
- **WBC often normal** (especially chronic)

**Imaging:**

**X-Ray:**
- **Periosteal reaction, lytic lesions** (only after 10-14 days, 30-50% bone loss needed)
- **Low sensitivity early**

**MRI (Gold Standard):**
- **Most sensitive/specific** (>90%)
- **Bone marrow edema, periosteal elevation, soft tissue involvement**
- **Distinguishes osteomyelitis from soft tissue infection**

**CT:**
- **Cortical destruction, sequestrum** (dead bone)
- **Surgical planning**

**Nuclear Medicine:**
- **Bone scan (Tc-99m):** Sensitive but non-specific (any bone turnover)
- **WBC scan (In-111):** More specific for infection

**Bone Biopsy (ESSENTIAL):**
- **Gold standard for diagnosis**
- **Obtain before antibiotics if possible**
- **Send for:**
  - **Gram stain, aerobic/anaerobic culture**
  - **Fungal/AFB culture** (if immunocompromised, chronic)
  - **Histopathology** (confirms infection)
- **Do NOT rely on swab/sinus tract culture** (poor correlation with bone culture)

### **Treatment:**

**General Principles:**
- **Obtain bone biopsy** before antibiotics (if feasible)
- **Pathogen-directed therapy** (based on culture)
- **Prolonged antibiotics** (≥6 weeks)
- **Surgery** if dead bone (sequestrum), abscess, instability

**Empiric Antibiotics (Until Culture Available):**

**Hematogenous:**
- **Vancomycin 15-20 mg/kg IV q8-12h** (if MRSA risk)
- OR **nafcillin 2g IV q4h** (if MSSA likely)

**Contiguous/Diabetic Foot:**
- **Vancomycin** + **pip-tazo 3.375-4.5g IV q6-8h** (polymicrobial coverage)
- OR **vancomycin** + **ceftriaxone 2g IV daily + metronidazole 500mg IV q8h**

**Pathogen-Directed Therapy:**

***S. aureus* (MSSA):**
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h × 6 weeks**
- **Oral step-down** (after 2-4 weeks IV, if improving): Cephalexin 500mg PO QID OR dicloxacillin 500mg PO QID

***S. aureus* (MRSA):**
- **Vancomycin 15-20 mg/kg IV q8-12h × 6 weeks** (target trough 15-20 for bone infection)
- **Alternatives:** Daptomycin 8-10 mg/kg IV daily (higher dose for bone), linezolid 600mg PO/IV BID

**Streptococci:**
- **Penicillin G 4 million units IV q4h** OR **ceftriaxone 2g IV daily × 4-6 weeks**

**Gram-Negatives (*E. coli*, *Pseudomonas*):**
- **Ceftriaxone 2g IV daily** OR **cefepime 2g IV q8h × 4-6 weeks**
- **Ciprofloxacin 750mg PO BID** (oral option for susceptible Gram-negatives)

**Anaerobes:**
- **Metronidazole 500mg IV/PO q8h** OR **clindamycin 600-900mg IV q8h**

**Duration:**
- **IV antibiotics:** 4-6 weeks (minimum)
- **Oral step-down:** After 2-4 weeks IV (if clinical improvement, low-risk pathogen)
- **Chronic osteomyelitis:** May need >6 weeks, especially if retained hardware

### **Surgical Management:**

**Indications:**
- **Dead bone (sequestrum)**
- **Abscess** (soft tissue, bone)
- **Instability** (vertebral)
- **Failed medical therapy**
- **Retained foreign body** (prosthetic, hardware)

**Procedures:**
- **Debridement** (remove dead bone, necrotic tissue)
- **Stabilization** (if pathologic fracture, vertebral instability)
- **Antibiotic beads** (PMMA with gentamicin/vancomycin)

### **Special Situations:**

**Vertebral Osteomyelitis:**
- **MRI spine** (most sensitive)
- **Blood cultures** (positive 50-70%)
- **CT-guided biopsy** (if blood cultures negative)
- **Antibiotics × 6-8 weeks** (longer if hardware, immunocompromised)
- **Surgery** if neurologic deficit, spinal instability, epidural abscess

**Diabetic Foot Osteomyelitis:**
- **"Probe-to-bone" test** (if probe touches bone = high sensitivity for osteomyelitis)
- **Bone biopsy** (if unclear)
- **Empiric polymicrobial coverage** (vancomycin + pip-tazo)
- **Surgical debridement** often needed (remove dead bone, improve perfusion)

**Chronic Osteomyelitis:**
- **Often relapsing**
- **Requires surgical debridement** (remove sequestrum)
- **Prolonged antibiotics** (>6 weeks)
- **May need suppressive therapy** (if cannot eradicate)

### **Prognosis:**

**Cure Rates:**
- **Acute hematogenous (no surgery):** 80-90%
- **Chronic (with surgery):** 60-80%
- **Diabetic foot:** Variable (depends on vascular status, debridement)

## Key Points

### **Bone Biopsy = Gold Standard:**
- **Do NOT treat based on swab/sinus tract culture**
- **Obtain bone culture before antibiotics** (if possible)

### **MRI = Best Imaging:**
- **Most sensitive/specific** (>90%)
- **X-ray insensitive early** (10-14 days delay)

### **Pathogen-Directed × 6 Weeks:**
- ***S. aureus* most common** (MSSA: nafcillin, MRSA: vancomycin)
- **IV 4-6 weeks** (oral step-down if improving, low-risk pathogen)

### **Surgery if Dead Bone:**
- **Debride sequestrum, abscess**
- **Antibiotics alone insufficient** if dead bone present

### **Diabetic Foot = Polymicrobial:**
- **Vancomycin + pip-tazo** (empiric)
- **Surgical debridement** often needed

### **Clinical Pearls:**
- **Bone biopsy essential** (do NOT rely on swab/sinus tract)
- **MRI best imaging** (X-ray insensitive early)
- ***S. aureus* most common** (nafcillin/vancomycin × 6 weeks)
- **Surgery if:** Dead bone, abscess, failed medical therapy
- **Diabetic foot:** Probe-to-bone test, polymicrobial coverage
- **Vertebral:** Blood cultures often positive (50-70%), MRI spine

## Sources

- [IDSA: Osteomyelitis Guidelines 2024]
- [CID: Diabetic Foot Osteomyelitis 2024]

## Media

N/A
